cme
Early Detection of Prostate Cancer
Dtsch Arztebl 2006; 103(37): A-2399
;
For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.
| 1. | De Koning HJ, Liem MK, Baan CA et al.: Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268–73. MEDLINE |
| 2. | Schmid HP, Riesen W, Prikler L: Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004; 50: 71–8. MEDLINE |
| 3. | Pienta KJ: Etiology, epidemiology and prevention of carcinoma of the prostate. In: Walsh PC, Retik A, Stamey TA, Vaughan EJ, Hrsg.: Campell´s Urology. Philadelphia: Saunders, 1997: 2489–96. |
| 4. | Statistisches Bundesamt. www.destatis.de/basis/d/gesu/gesutab20.php |
| 5. | Fachgesellschaften (2002): AWMF: S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms). www.awmf-online.de. |
| 6. | Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J: The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127–32. MEDLINE |
| 7. | Luboldt H, Rubben H: PSA – Früherkennung des Prostatakarzinoms. Urologe A 2000; 39: 22–6. MEDLINE |
| 8. | Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ: Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/mL or less. J Urol 1999; 161(3): 835–9. MEDLINE |
| 9. | Ellis WJ, Chetner MP, Preston SD, Brawer MK: Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994; 152: 1520–5. MEDLINE |
| 10. | Flanigan RC, Catalona WJ, Richie JP et al.: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 1994; 152:1506–9. MEDLINE |
| 11. | Loch T, Leuschner I, Genberg C et al.: Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma. Urologe A 2000; 39: 341–7. MEDLINE |
| 12. | Loch T, Eppelmann U, Lehmann J, Wullich B, Loch A, Stockle M: Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions. World J Urol 2004; 22: 357–60. MEDLINE |
| 13. | Brawer MK, Chetner MP: Ultrasonography and biopsy of the prostate. In: Walsh PC, Retik A, Stamey TA, Vaughan EJ, eds.: Campell´s Urology. Philadelphia: Saunders, 1997: 2506–18. |
| 14. | Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schroder FH: Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60(5): 826–30. MEDLINE |
| 15. | Hoedemaeker RF, Rietbergen JB, Kranse R, Schroder FH, van der Kwast TH: Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 2000; 164(2): 411–15. MEDLINE |
| 16. | Catalona WJ, Smith DS, Wolfert RL et al.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20. MEDLINE |
| 17. | Luboldt HJ, Altwein JE, Bichler KH, Czaja D et al.: Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle. Urologe A 1999; 38(2):114–23. MEDLINE |
| 18. | Price CP, Allard J, Davies G et al.: Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 2001; 38(Pt 3):188–216. MEDLINE |
| 19. | Thompson IM, Goodman PJ, Tangen CM et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–24. MEDLINE |
| 20. | Carter HB, Epstein JI, Partin AW: Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53:126–30. MEDLINE |
| 21. | Catalona WJ, Loeb S: The PSA era is not over for prostate cancer. Eur Urol 2005; 48: 541–5. |
| 22. | Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977–84. MEDLINE |
| 23. | Van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH: Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95:1462–6. MEDLINE |
| 24. | Klotz L: Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172: 48–50. MEDLINE |
